Log In
BCIQ
Print this Print this
 

SensiGene RHD LDT, SensiGene Rhesus D Fetal Genotyping test

  Manage Alerts
Collapse Summary General Information
Company Laboratory Corp. of America Holdings
DescriptionNon-invasive fetal Rhesus D (RhD) genotyping test that detects circulating cell-free fetal DNA in maternal blood
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationAutoimmune, Diagnostic
Indication DetailsDetect fetal Rhesus D (RhD) incompatibility in RhD-negative pregnant women
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$302.0M

$302.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/07/2016

$302.0M

$302.0M

0

Get a free BioCentury trial today